(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 October 2010 (07.10.2010)

PCT

(10) International Publication Number
WO 2010/114824 A8

(51) International Patent Classification:
A01N 35/00 (2006.01) *A61K 31/12* (2006.01)

(21) International Application Number:
PCT/US2010/029172

(22) International Filing Date:
30 March 2010 (30.03.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/164,523 30 March 2009 (30.03.2009) US
61/309,348 1 March 2010 (01.03.2010) US

(71) Applicant *(for all designated States except US)*: **TRANSTECH PHARMA, INC.** [US/US]; 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MJALLI, Adnan M.M.** [US/US]; 6421 Ashton Park Drive, Oak Ridge, North Carolina 27310 (US). **BEHME, Christopher** [US/US]; 3392 Cherrybrook Drive, Jamestown, North Carolina 27282 (US). **CHRISTEN, Daniel P.** [CH/US]; 3345 Winter Brook Place, Jamestown, North Carolina 27282 (US). **POLISETTI, Dharma Rao** [IN/US]; 3741 Deerfield Street, High Point, North Carolina 27265 (US). **QUADA, James** [US/US]; 3605 Nina Court, High Point, North Carolina 27265 (US). **SANTHOSH, Kalpathy** [IN/US]; 4132 Tutbury Drive, Jamestown, North Carolina 27282 (US). **BONDLELA, Muralidhar** [IN/US]; 6527 Overland Park Drive, Greensboro, North Carolina 27410 (US). **GUZEL, Mustafa** [TR/US]; 4058 Gunsmith Court, Jamestown, North Carolina 27282 (US). **YARRAGUNTA, Ravindra Reddy** [IN/US]; 5001 Bass Chapel Rd. Apt. #1A, Greensboro, North Carolina 27455 (US). **GOHIMUKKULA, Devi Reddy** [US/US]; 4061 Cobbler Court, Jamestown, North Carolina 27282 (US). **ANDREWS, Robert Carl** [US/US]; 3312 Morris Farm Drive, Jamestown, North Carolina 27282 (US). **DAVIS, Stephen Thomas** [US/US]; 1 Wateroaks Court, Durham, North Carolina 27703 (US). **YOKUM, Thomas Scott** [US/US]; 5108 Hartridge Way, Greensboro, North Carolina 27407 (US). **FREEMAN, Jennifer, L.R.** [US/US]; 154 Surtees Road, Winston-Salem, NC 27104 (US).

(74) Agents: **DAILEY, Robert, Scott** et al.; TransTech Pharma, Inc., 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
6 October 2011

(15) Information about Correction:
see Notice of 6 October 2011

WO 2010/114824 A8

(54) Title: SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

(57) Abstract: The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.